Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations a review of the clinical evidence
This report will review the available evidence on the clinical effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults with HIV infections, sickle cell disease, those who have undergone either hematopoietic stem cell or solid organ transplant, those receiving immunosuppressiv...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
2014, 27 March 2014
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | This report will review the available evidence on the clinical effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults with HIV infections, sickle cell disease, those who have undergone either hematopoietic stem cell or solid organ transplant, those receiving immunosuppressive treatment, and those who are 65 years of age and older |
|---|---|
| Item Description: | Title from PDF caption |
| Physical Description: | 1 PDF file (20 pages) illustrations |